Ampio Pharmaceuticals (AMPE) 10-Q 6 May 20 2020 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2020	Apr. 30, 2020
Document And Entity Information [Abstract]
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Entity Registrant Name	AMPIO PHARMACEUTICALS, INC.
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		164,851,000
Entity Central Index Key	0001411906
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Amendment Flag	false

Balance Sheets

Balance Sheets - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 2,415,000	$ 6,532,000
Prepaid expenses and other	1,020,000	1,718,000
Total current assets	3,435,000	8,250,000
Fixed assets, net	4,453,000	4,748,000
Right-of-use asset	959,000	1,003,000
Total assets	8,847,000	14,001,000
Current liabilities
Accounts payable and accrued expenses	4,214,000	4,025,000
Lease liability-current portion	265,000	259,000
Total current liabilities	4,479,000	4,284,000
Lease liability-long-term	1,142,000	1,210,000
Warrant derivative liability	1,233,000	2,064,000
Total liabilities	6,854,000	7,558,000
Commitments and contingencies (Note 7)
Stockholders’ equity
Preferred Stock, par value $0.0001; 10,000,000 shares authorized; none issued
Common Stock, par value $0.0001; 300,000,000 shares authorized as of 2020 and 2019; shares issued and outstanding - 160,022,000 as of March 31, 2020 and 158,645,000 as of December 31, 2019	16,000	16,000
Additional paid-in capital	191,789,000	191,060,000
Accumulated deficit	(189,812,000)	(184,633,000)
Total stockholders’ equity	1,993,000	6,443,000
Total liabilities and stockholders’ equity	$ 8,847,000	$ 14,001,000

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred Stock, par value	$ 0.0001	$ 0.0001
Preferred Stock, shares authorized	10,000,000	10,000,000
Preferred Stock, shares issued	0	0
Common Stock, par value	$ 0.0001	$ 0.0001
Common Stock, shares authorized	300,000,000	300,000,000
Common Stock, shares issued	160,022,000	158,645,000
Common Stock, shares outstanding	160,022,000	158,645,000

Statements of Operations

Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating expenses
Research and development	$ 4,254,000	$ 1,564,000
General and administrative	1,767,000	1,112,000
Total operating expenses	6,021,000	2,676,000
Other income (expense)
Interest income (expense)	11,000	24,000
Derivative gain	831,000	(3,160,000)
Total other income (expense)	842,000	(3,136,000)
Net (loss) income	$ (5,179,000)	$ (5,812,000)
Net (loss) income per common share: Basic	$ (0.03)	$ (0.05)
Net (loss) income per common share: Diluted	$ (0.04)	$ (0.05)
Weighted average number of common shares outstanding: Basic	159,054,000	111,104,000
Weighted average number of common shares outstanding: Diluted	160,558,000	111,104,000

Statements of Stockholders' Equ

Statements of Stockholders' Equity - USD ($)	Common Stock [Member]	Additional Paid-in Capital	Accumulated Deficit	Total
Beginning Balance at Dec. 31, 2018	$ 11,000	$ 176,228,000	$ (171,003,000)	$ 5,236,000
Beginning Balance, shares at Dec. 31, 2018	110,942,000
Issuance of common stock for services	$ 0	60,000	0	60,000
Issuance of common stock for services (Shares)	136,000
Stock-based compensation, net	$ 0	28,000	0	28,000
Warrants exercised, net	$ 0	20,000	0	20,000
Warrants exercised, net (Shares)	50,000
Net (loss) income	$ 0	0	(5,812,000)	(5,812,000)
Ending Balance at Mar. 31, 2019	$ 11,000	176,336,000	(176,815,000)	(468,000)
Ending Balance, shares at Mar. 31, 2019	111,128,000
Beginning Balance at Dec. 31, 2019	$ 16,000	191,060,000	(184,633,000)	6,443,000
Beginning Balance, shares at Dec. 31, 2019	158,645,000
Issuance of common stock for services	$ 0	80,000	0	80,000
Issuance of common stock for services (Shares)	136,000
Stock-based compensation, net	$ 0	213,000	0	213,000
Issuance of common stock in connection with the equity distribution agreement	$ 0	682,000	0	682,000
Issuance of common stock in connection with the equity distribution agreement (in shares)	1,241,000
Offering costs related to the issuance of common stock in connection with the equity distribution agreement	$ 0	(246,000)	0	(246,000)
Net (loss) income	0	0	(5,179,000)	(5,179,000)
Ending Balance at Mar. 31, 2020	$ 16,000	$ 191,789,000	$ (189,812,000)	$ 1,993,000
Ending Balance, shares at Mar. 31, 2020	160,022,000

Statements of Cash Flows

Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities
Net (loss) income	$ (5,179,000)	$ (5,812,000)
Adjustments to reconcile net (loss) income to net cash used in operating activities
Stock-based compensation, net	213,000	28,000
Depreciation and amortization	295,000	365,000
Issuance of common stock for services	80,000	60,000
Derivative loss (gain)	(831,000)	3,160,000
Changes in operating assets and liabilities
Increase in prepaid expenses and other	698,000	(180,000)
Increase (decrease) in accounts payable and accrued expenses	189,000	(5,000)
Decrease in lease liability	(18,000)	(56,000)
Net cash used in operating activities	(4,553,000)	(2,440,000)
Cash flows used in investing activities
Purchase of fixed assets	0	(5,000)
Net cash used in investing activities	0	(5,000)
Cash flows from financing activities
Proceeds from sale of common stock in connection with the equity distribution agreement	682,000	0
Costs related to sale of common stock in connection with the equity distribution agreement	(246,000)	0
Proceeds from warrant exercises	0	20,000
Net cash provided by financing activities	436,000	20,000
Net change in cash and cash equivalents	(4,117,000)	(2,425,000)
Cash and cash equivalents at beginning of period	6,532,000	7,585,000
Cash and cash equivalents at end of period	2,415,000	5,160,000
Non-cash transactions:
Initial lease liability arising from the adoption of ASU 2016-02	0	1,704,000
Initial recognition of right-of-use asset arising from the adoption of ASU 2016-02	$ 0	$ 1,168,000

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2020
Basis of Presentation
Basis of Presentation	Note 1 - Basis of Presentation The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions of the Securities and Exchange Commission (“SEC”) on Quarterly Reports on Form 10‑Q and Article 8 of Regulation S-X. Accordingly, such financial statements do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of the financial position and of the results of operations and cash flows of Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) for the periods presented. These financial statements should be read in conjunction with the audited financial statements and accompanying notes thereto for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10‑K filed with the SEC on February 21, 2020 (the “2019 Annual Report”). The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year. The balance sheet at December 31, 2019 was derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. Impact of Global Pandemic In March 2020, the World Health Organization declared the outbreak of the novel coronavirus, COVID-19, a global pandemic. The ultimate extent to which COVID-19, and measures taken in response to it, will impact the Company’s business is highly uncertain and subject to change. The full extent of potential impacts on the Company’s business and product development, including clinical trials, financing activities and the global economy are still unknown and cannot be predicted due to the uncertain nature of the COVID-19 pandemic and its effects. However, these effects could have a material adverse impact on the Company’s business, operations, financial condition and results of operations. Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts or foreign currency hedging arrangements. The Company maintains cash and cash equivalent balances in the form of bank demand deposits, United States federal government backed treasury securities and fully liquid money market fund accounts with financial institutions that management believes are creditworthy. The Company periodically monitors its cash positions with, and the credit quality of, the financial institutions with which it invests. During the three months ended March 31, 2020, and as consistent with prior reporting periods, the Company maintained balances in excess of federally insured limits. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, and related disclosures in the financial statements and accompanying notes. The Company bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions primarily include the Company’s accrual for its current Phase III clinical trial (the “AP-013 study”) of Ampion for treatment of severe OAK, projected future liquidity and resulting going concern position, warrant derivative liability and related periodic gains and losses, stock-based compensation, the projected useful lives and potential impairment of fixed assets, and the valuation allowance related to deferred tax assets. The Company develops these estimates using its judgment based upon the facts and circumstances known at the time. Adoption of Recent Accounting Pronouncements In August 2018, the FASB issued ASU 2018‑13, “ Fair Value Measurement - Disclosure Framework (Topic 820) ”. The updated guidance modified the disclosure requirements on fair value measurements. The updated guidance is effective for fiscal years beginning after December 15, 2019, including interim reporting periods within those fiscal years. The Company adopted ASU 2018-13 during the first quarter of 2020 and the adoption of this guidance did not have a material impact on the Company’s financial statements. Recent Accounting Pronouncements The Company reviewed the recent accounting pronouncements and determined that none of the recent accounting pronouncements were applicable. This Quarterly Report on Form 10-Q does not discuss recent pronouncements that are not anticipated to have a current and/or future impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures

Going Concern

Going Concern	3 Months Ended
	Mar. 31, 2020
Going Concern
Going Concern	Note 2 - Going Concern As of and for the three months ended March 31, 2020, the Company had cash and cash equivalents of $2.4 million and a net loss of $5.2 million. The net loss is primarily attributable to operating expenses of $6.0 million, partially offset with the non-cash derivative gain of $0.8 million that was recognized during the three months ended March 31, 2020. The Company used net cash in operations of $4.5 million for the three months ended March 31, 2020. As of March 31, 2020, the Company had an accumulated deficit of $189.8 million and stockholders’ equity of $2.0 million. In addition, as a clinical stage biopharmaceutical company, the Company has not generated any revenues or profits to date. These existing and on-going factors continue to raise substantial doubt about the Company’s ability to continue as a going concern. During the three months ended March 31, 2020, the Company entered into a Sales Agreement (“Sales Agreement”) with two agents to implement an “at-the-market” (“ATM”) equity offering program under which the Company, at its sole discretion, may issue and sell from time to time shares of its common stock. During the three months ended March 31, 2020, the Company sold shares pursuant to the ATM equity offering program, which sales yielded gross proceeds of $0.7 million (see Note 9 ). The Company has prepared an updated projection covering the period from April 1, 2020 through March 31, 2021 based on the requirements of ASC 205-40, “ Going Concern ”, which reflects cash requirements for fixed, on-going expenses such as payroll, legal and accounting, patents and overhead at an average cash burn rate of approximately $0.8 million per month. The Company is assessing the impact of the COVID-19 pandemic on the AP‑013 study, and, as such, is not currently in a position to project the required liquidity needs for completion of the study. With the receipt of the loan proceeds from the PPP in April 2020 (see Note 13 ), combined with the planned disciplined use of the ATM equity offering program, it is possible that the Company may have sufficient liquidity to fund operations into first quarter of 2021 . This projection is based on many assumptions that may prove to be incorrect, including, but not limited to, the overall effectiveness of sourcing requisite capital through the ATM equity offering program in a manner that is not materially detrimental to the Company. As such, it is possible that the Company could exhaust its available cash and cash equivalents earlier than presently anticipated. In addition, the global COVID-19 pandemic continues to rapidly evolve and its effect on the Company’s operations and ability to raise capital through the ATM equity offering program, or otherwise, is currently highly uncertain and subject to change. The Company expects to seek additional capital investments in both the near and long-term to enable it to support its business operations, including specifically (i) clinical development, (ii) BLA preparation and submission, (iii) existing base business operations and (iv) commercial development activities for Ampion. The Company will continue to closely monitor and evaluate the overall capital markets to determine the appropriate timing for such capital raise, which will primarily depend on existing market conditions relative to the Company’s need for funds at such time. However, the Company cannot give any assurance that it will be successful in satisfying its future cash needs in a manner that will be sufficient to fund its operations. The accompanying unaudited interim financial statements were prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of recorded assets or the classification of liabilities, which adjustments may be necessary should the Company be unable to continue as a going concern.

Prepaid Expenses and Other

Prepaid Expenses and Other	3 Months Ended
	Mar. 31, 2020
Prepaid Expenses and Other
Prepaid Expenses and Other	Note 3 – Prepaid Expenses and Other Prepaid expenses and other balances as of March 31, 2020 and December 31, 2019 are as follows: March 31, 2020 December 31, 2019 Clinical trial deposit $ 348,000 $ 946,000 Insurance premiums 229,000 502,000 BLA consulting services deposit 182,000 182,000 Other 146,000 29,000 Annual service agreements 81,000 25,000 Lease deposit 34,000 34,000 Total prepaid expenses and other $ 1,020,000 $ 1,718,000

Fixed Assets

Fixed Assets	3 Months Ended
	Mar. 31, 2020
Fixed Assets
Fixed Assets	Note 4 – Fixed Assets Fixed assets are recorded at cost and, once placed in service, are depreciated on the straight-line method over their estimated useful lives. Leasehold improvements are accreted over the shorter of the estimated economic life or related lease term. Fixed assets consist of the following: Estimated As of December 31, As of March 31, Useful Lives in Years 2019 Additions Disposals 2020 Manufacturing facility/clean room 3 - 8 $ 3,081,000 $ — $ — $ 3,081,000 Leasehold improvements 10 6,075,000 — — 6,075,000 Office furniture and equipment 5 - 10 520,000 — — 520,000 Lab equipment 5 - 8 1,137,000 — — 1,137,000 Less accumulated depreciation and amortization (6,065,000) (295,000) — (6,360,000) Fixed assets, net $ 4,748,000 $ (295,000) $ — $ 4,453,000 Depreciation and amortization expense for the respective periods is as follows: Three Months Ended March 31, 2020 2019 Depreciation and amortization expense $ 295,000 $ 365,000

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	3 Months Ended
	Mar. 31, 2020
Accounts Payable and Accrued Expenses
Accounts Payable and Accrued Expenses	Note 5 – Accounts Payable and Accrued Expenses Accounts payable and accrued expenses as of March 31, 2020 and December 31, 2019 are as follows: March 31, 2020 December 31, 2019 Accounts payable $ 1,226,000 $ 151,000 Clinical trial 2,563,000 3,288,000 Professional fees 377,000 317,000 Property taxes 25,000 96,000 Other 18,000 30,000 BLA consulting services 5,000 28,000 Insurance premiums — 21,000 Accrued compensation — 72,000 Director fees — 22,000 Accounts payable and accrued expenses $ 4,214,000 $ 4,025,000

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 6 - Commitments and Contingencies Commitments and contingencies are described below and summarized by the following table: Total 2020 2021 2022 2023 2024 Thereafter Key clinical research trial obligations $ 2,193,000 $ 2,193,000 $ — $ — $ — $ — $ — BLA consulting services 1,143,000 — 1,143,000 — — — — Statistical analysis and programming consulting services 350,000 350,000 — — — — — Employment agreements 1,911,000 649,000 783,000 466,000 13,000 — — $ 5,597,000 $ 3,192,000 $ 1,926,000 $ 466,000 $ 13,000 $ — $ — Key Clinical Research Trial Obligations In March 2019, the Company entered into a contract with a clinical research organization (“CRO”) in connection with the AP-013 study totaling $6.2 million and covering an initial clinical trial size of 724 patients, which was increased by $4.1 million in January 2020 as a result of an increase in number of patients to 1,034 resulting in the CRO contract commitment totaling $10.3 million. From the inception of this contract through March 31, 2020, the Company incurred and accrued cumulative costs totaling $8.3 million against the contract. This contract had an outstanding obligation for future costs and services totaling $1.9 million as of March 31, 2020. In March 2020, recognizing the challenges due to the global COVID-19 pandemic, the Company announced the close of patient enrollment in the AP-013 study. The Company is exploring options to enable it to complete the AP-013 study; however, it is possible that the COVID-19 pandemic may prevent completion of the AP-013 study at this time or at all. Due to the uncertainty resulting from COVID-19, the future contractual commitment amount related to the AP-013 study may change. The following table provides further detail of the Company’s current contractual obligations for the conduct of the AP-013 study, which does not include any changes related to the potential impact of COVID-19, as such impacts are unknown and cannot be reasonably estimated at the date of this filing: March 31, 2020 Original contract $ 6,180,000 Amendment to contract 4,075,000 Total Contract $ 10,255,000 Initial deposit (included in original contract amount) $ 861,000 Amendment to deposit 699,000 Expenses incurred applied to deposit (1,212,000) Remaining Deposit $ 348,000 Expenses incurred/accrued (includes expenses applied to deposit) $ 8,314,000 Total future commitment $ 1,941,000 In June 2019, the Company entered into a contract with a patient recruitment services company in connection with the AP-013 study totaling $264,000. In September 2019, the Company finalized contract negotiations to increase the contract to $377,000 as a result of an increased number of patients, from 724 to 1,034, required for the study. In January 2020, the Company finalized contract negotiations to increase the contract to $698,000 as a result of increased advertising for the AP-013 study. The Company estimates that it incurred an additional $20,000 of expense relating to printing supplies for this contract. Therefore, the Company expects the contract to total $718,000. The Company had incurred cumulative costs under the current contract totaling $718,000 and had no outstanding obligation as of March 31, 2020. In November 2019, the Company entered into a contract with a clinical staff outsourcing firm to assist with the AP-013 study, with an adjusted estimated cost totaling approximately $463,000 as of March 31, 2020. The Company had incurred and accrued cumulative costs under the current contract totaling $211,000 and had outstanding future obligations totaling $252,000 as of March 31, 2020. BLA Consulting Services In March 2018, the Company entered into a BLA consulting services agreement for $1.2 million. This contract required a deposit of $364,000, of which $182,000 was funded and is recorded within the “prepaid expenses and other” line item on the balance sheet. The Company incurred cumulative costs totaling $69,000 against this contract and had outstanding obligations totaling $1.1 million as of March 31, 2020. This contract does not have an expiration date. The Company incurs costs under the contract as sections of the BLA are drafted for the submission of the complete BLA to the U.S. Food and Drug Administration (“FDA”). Due to the unknown impact of COVID-19 on the AP-013 study specifically, and the Company’s operations generally, at the date of this filing, the Company expects the incurrence of the remaining costs associated with the preparation of the BLA filing to be postponed until fiscal 2021. Statistical Analysis and Programming Consulting Services In May 2019, Ampio entered into a statistical analysis and programming consulting services agreement for $578,000. The Company had incurred cumulative costs totaling $228,000 against the contract as of March 31, 2020 and, as such, had an outstanding obligation of $350,000 at March 31, 2020. Employment Agreements On December 14, 2019, the Company entered into a new three-year employment agreement with Mr. Macaluso, Chief Executive Officer, which became effective January 10, 2020, immediately following the expiration of his prior employment agreement. The new employment agreement provides for an annual salary of $300,000 and term ending January 10, 2023, subject to certain automatic renewal provisions. On September 16, 2019, the Company entered into a new two-year employment agreement with Ms. Cherevka, Chief Operating Officer, which by its terms cancelled the previous employment agreement on such date. The new employment agreement provides for an annual salary of $280,000 and a term ending September 16, 2021, subject to certain automatic renewal provisions. The Company entered into an employment agreement with Mr. Daniel Stokely, Chief Financial Officer, on July 9, 2019, which provided for an annual salary of $285,000 and a term beginning July 31, 2019 and lasting for three years, subject to certain automatic renewal provisions. The employment agreement, as amended in December 2019, allowed for reimbursement of reasonable commuting and relocation expenses for up to eight months. The commuting and relocation expenses were incurred in full as of March 31, 2020. Amounts noted above do not assume the continuation of employment beyond the contractual terms of each employee’s existing employment agreements. Facility Lease In December 2013, the Company entered into a 125-month non-cancellable operating lease for office space and a manufacturing facility. The effective date of the lease was May 1, 2014. The initial base rent of the lease was $23,000 per month. The total base rent over the term of the lease is approximately $3.3 million, which includes rent abatements and leasehold incentives. The Company adopted the FASB issued ASC 842, “Leases (Topic 842)” effective January 1, 2019. With the adoption of ASC 842, the Company recorded an operating ROU asset and an operating lease liability on its balance sheet. The ROU asset represents the Company’s right to use the underlying asset for the lease term and the lease obligation represents the Company’s commitment to make the lease payments arising from the lease. ROU lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company’s lease does not provide an implicit rate, the Company used an estimated incremental borrowing rate 5.75% based on the information available at the commencement date in determining the present value of the lease payments. Lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectations regarding the terms. The lease liability is classified as current or long-term on the balance sheet. The following table provides a reconciliation of the Company’s remaining undiscounted payments for its facility lease and the carrying amount of the lease liability presented in the balance sheet as of March 31, 2020: Facility Lease Payments 2020 2021 2022 2023 2024 Thereafter Remaining Facility Lease Payments $ 1,597,000 $ 253,000 $ 345,000 $ 355,000 $ 364,000 $ 280,000 $ — Less: Discount Adjustment (190,000) Total lease liability $ 1,407,000 Lease liability-current portion $ 265,000 Long-term lease liability $ 1,142,000 The following table provides a reconciliation of the Company’s remaining ROU asset for its facility lease presented in the balance sheet as of March 31, 2020: Right-of-Use Asset Balance as of December 31, 2019 $ 1,003,000 Amortization (44,000) Balance as of March 31, 2020 $ 959,000 The Company recorded lease expense in the respective periods is as follows: Three Months Ended March 31, 2020 2019 Lease expense $ 67,000 $ 66,000

Warrants

Warrants	3 Months Ended
	Mar. 31, 2020
Warrants
Warrants	Note 7 – Warrants The Company has issued equity-classified warrants and liability warrants in conjunction with previous equity raises. The Company had a total of 2.7 million equity-classified warrants and 4.4 million liability warrants outstanding as of March 31, 2020. The following table summarizes the Company’s warrant activity: Weighted Weighted Average Number of Average Remaining Warrants Exercise Price Contractual Life Outstanding at December 31, 2019 7,116,000 $ 0.57 Warrants issued — $ — Warrants exercised — $ — Warrants expired — $ — Outstanding at March 31, 2020 7,116,000 $ 0.57 3.16 The total value for the warrant derivative liability as of March 31, 2020 is approximately $1.2 million. See Note 8 for additional information regarding the warrant derivative liability.

Fair Value Considerations

Fair Value Considerations	3 Months Ended
	Mar. 31, 2020
Fair Value Considerations [Abstract]
Fair Value Considerations	Note 8 - Fair Value Considerations Authoritative guidance defines fair value as the price that would be received upon the sale of an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The guidance establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources not affiliated with the Company. Unobservable inputs are inputs that reflect the Company’s assumptions of what market participants would use in pricing the asset or liability based on the best information available in the circumstances. The hierarchy is broken down into three levels based on reliability of the inputs as follows: Level 1: Inputs that reflect unadjusted quoted prices in active markets that are accessible to the Company for identical assets or liabilities; Level 2: Inputs that include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and Level 3: Unobservable inputs that are supported by little or no market activity. The Company’s financial instruments include cash and cash equivalents, accounts payable and accrued expenses, and warrant derivative liability. Warrants are recorded at estimated fair value-based utilization of the Black-Scholes warrant pricing model. The Company’s assets and liabilities which are measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. The Company’s policy is to recognize transfers in and/or out of the fair value hierarchy as of the date in which the even or change in circumstances caused the transfer. The Company has consistently applied the valuation techniques in all periods presented. The following table presents the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2020 and December 31, 2019, by level within the fair value hierarchy: Fair Value Measurements Using Level 1 Level 2 Level 3 Total March 31, 2020 Liabilities: Warrant derivative liability $ — $ — $ 1,233,000 $ 1,233,000 December 31, 2019 Liabilities: Warrant derivative liability $ — $ — $ 2,064,000 $ 2,064,000 The warrant derivative liability for both periods presented was valued using the Black-Scholes valuation methodology because that model embodies all the relevant assumptions that address the features underlying these instruments. The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as Level 3 in the fair value hierarchy: Derivative Instruments Balance as of December 31, 2019 $ 2,064,000 Warrant exercises — Change in fair value (831,000) Balance as of March 31, 2020 $ 1,233,000

Common Stock

Common Stock	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Common stock	Note 9 - Common Stock Authorized Shares The Company had 300.0 million authorized shares of common stock as of March 31, 2020 and December 31, 2019. The following table summarizes the Company’s remaining authorized shares available for future issuance: March 31, 2020 Authorized shares 300,000,000 Common stock outstanding 160,022,000 Options Outstanding 6,240,000 Warrants Outstanding 7,116,000 Reserved for issuance under 2019 Stock and Incentive Plan 9,516,000 Available shares 117,106,000 Average Stock Price: 30 day $ 0.48 60 day $ 0.57 90 day $ 0.60 Shelf Registration In March 2017, the Company filed a shelf registration statement on Form S‑3 (the “Prior Shelf Registration Statement”) with the SEC to register the Company’s common stock, preferred stock, debt securities, warrants and units in an aggregate amount of up to $100.0 million for offerings from time to time, as well as 5.0 million shares of common stock available for sale by selling shareholders. The Prior Shelf Registration Statement was declared effective in April 2017 by the SEC and was terminated in May 2020. In April 2020, the Company filed a shelf registration statement on Form S-3 (the “New Shelf Registration Statement”) with the SEC to register the Company’s common stock, preferred stock, debt securities, warrants and units in an aggregate amount of up to $100.0 million for offerings from time to time, which was declared effective in May 2020. However, the Company’s ability to issue and sell securities under the New Shelf Registration Statement may be limited, based on many factors including, but not limited to, the volatility of the Company’s stock price, the trading volume of the Company’s stock, and the number of remaining authorized shares available for the Company to issue. Sales Agreement In February 2020, the Company entered into a Sales Agreement with two agents to implement an ATM equity offering program under which the Company, from time to time and at its sole discretion, may offer and sell shares of its common stock having an aggregate offering price up to $50.0 million to the public through the agents. Subject to the terms and conditions of the Sales Agreement, the agents shall use their commercially reasonable efforts to sell shares from time to time, based upon the Company’s instructions as documented on a purchase notification form. The Company has no obligation to sell any shares and may, at any time and at its sole discretion, suspend sales under the Sales Agreement or terminate the Sales Agreement in accordance with its terms. The Company provided the agents with customary indemnification rights, and the agents will be entitled to an aggregate fixed commission of 4.0% of the gross proceeds (2.0% to each agent) to the Company of the shares sold. The following table summarizes the Company’s sales and related issuance costs incurred under the Sales Agreement as of March 31, 2020: Sales Agreement Total shares of common stock sold 1,241,000 Average price per share $ 0.58 Gross Proceeds $ 682,000 Commissions earned by placement agents (27,000) Legal/Audit fees (219,000) Net Proceeds $ 436,000 Common Stock Issued for Services In accordance with the non-employee directors’ compensation package, the Company issued 136,000 and 136,000 shares of common stock valued at $80,000 and $60,000, during the period ended March 31, 2020 and 2019, respectively.

Equity

Equity	3 Months Ended
	Mar. 31, 2020
Equity
Equity	Note 10 - Equity Options In December 2019, the Company’s Board of Directors and stockholders approved the adoption of the Ampio Pharmaceuticals, Inc. 2019 Stock and Incentive Plan (the “2019 Plan”), under which shares were reserved for future issuance of equity related awards classified as option awards/grants, restricted stock awards and other equity related awards. The 2019 Plan permits grants of equity awards to employees, directors and consultants. The stockholders approved a total of 10.0 million shares to be reserved for issuance under the 2019 Plan. The Company’s previous 2010 Stock and Incentive Plan (the “2010 Plan”) was cancelled concurrently with the adoption of the 2019 Plan. The following table summarizes the activity of the 2019 Plan and the available options to be granted as of March 31, 2020: 2019 Plan Total shares reserved for equity awards 10,000,000 Options granted (484,000) Remaining shares available for future equity awards 9,516,000 The following table summarizes the Company’s stock option activity under both the 2010 Plan and 2019 Plan: Weighted Weighted Average Number of Average Remaining Aggregate Options Exercise Price Contractual Life Intrinsic Value Outstanding at December 31, 2019 6,000,000 $ 1.33 5.40 $ — Granted 340,000 $ 0.69 Forfeited (100,000) $ 1.70 Outstanding at March 31, 2020 6,240,000 $ 1.29 5.45 $ 1,350 Exercisable at March 31, 2020 5,717,000 $ 1.36 5.08 $ 1,350 The 100,000 stock options that were forfeited as of March 31, 2020 were issued under the 2010 Plan, which was cancelled as noted above. Therefore, these forfeited stock options were not added back to the 2019 Plan. Stock options outstanding at March 31, 2020 are summarized in the table below: Number of Weighted Weighted Average Options Average Remaining Range of Exercise Prices Outstanding Exercise Price Contractual Lives $0.40 - $2.00 5,212,000 $ 0.73 6.13 $2.01 - $5.00 840,000 $ 3.28 1.68 $5.01 - $8.62 188,000 $ 7.97 3.60 6,240,000 $ 1.29 5.45 The Company computes the fair value for all options granted or modified using the Black-Scholes option pricing model. To calculate the fair value of the options, certain assumptions are made regarding components of the model, including the fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to the valuation. The Company calculates its volatility assumption using the actual changes in the market value of its stock. Forfeitures are recognized as they occur. The Company’s historical option exercises do not provide a reasonable basis to estimate an expected term due to the lack of sufficient data. Therefore, the Company estimates the expected term by using the simplified method. The simplified method calculates the expected term as the average of the vesting term plus the contractual life of the options. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity. The Company computed the fair value of options granted during the period ended March 31, 2020, using the following assumptions: Expected volatility 130.73% - 131.18 % Risk free interest rate 1.62% - 1.67 % Expected term (years) 5.00 - 5.51 Stock-based compensation expense related to the fair value of stock options is included in the statements of operations as research and development expenses or general and administrative expenses as set forth in the table below. The following table summarizes stock-based compensation expense for the three months ended March 31, 2020 and 2019: Three Months Ended March 31, 2020 2019 Research and development expenses Stock-based compensation $ 59,000 $ — General and administrative expenses Issuance of common stock for services 80,000 60,000 Stock-based compensation 154,000 28,000 Total stock-based compensation $ 293,000 $ 88,000 Unrecognized expense at March 31, 2020 119,000 Weighted average remaining years to vest 0.52

Earnings Per Share

Earnings Per Share	3 Months Ended
	Mar. 31, 2020
Earnings Per Share
Earnings Per Share	Note 11 - Earnings Per Share Basic earnings per share is computed by dividing net loss available to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is based on the treasury stock method and computed by dividing net loss available to common stockholders by the diluted weighted-average shares of common stock outstanding during each period. The Company’s potentially dilutive shares include stock options and warrants for the shares of common stock. The potentially dilutive shares are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when the effect is dilutive. The investor warrants are treated as equity in the calculation of diluted earnings per share in both the computation of the numerator and denominator. The following table sets forth the calculations of basic and diluted earnings per share for the three months ended March 31, 2020 and 2019: Three Months Ended March 31, 2020 2019 Net loss $ (5,179,000) $ (5,812,000) Less: decrease in fair value of investor warrants (831,000) — Loss available to common stockholders $ (6,010,000) $ (5,812,000) Basic and diluted weighted-average common shares outstanding 159,054,000 111,104,000 Add: dilutive effect of equity instruments 1,504,000 — Diluted weighted-average shares outstanding 160,558,000 111,104,000 Earnings per share – basic $ (0.03) $ (0.05) Earnings per share – diluted $ (0.04) $ (0.05) The potentially dilutive shares of common stock that have been excluded from the calculation of net loss per share because of the anti-dilutive effect are as following: Three Months Ended March 31, 2020 2019 Outstanding stock options 5,948,000 5,426,000 Warrants to purchase shares of common stock 5,904,000 22,233,000 Total potentially dilutive shares of common stock 11,852,000 27,659,000

Litigation

Litigation	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Litigation	Note 12 – Litigation On August 25, 2018, a purported stockholder of the Company commenced a putative class action lawsuit in the United States District Court for the Central District of California, captioned Shi v. Ampio Pharmaceuticals, Inc., et al., Case No. 18-cv-07476 (the “Securities Class Action”). Plaintiff in the Securities Class Action alleges that the Company and certain of its current and former officers violated the federal securities laws by misrepresenting and/or omitting material information regarding the AP-003 Phase III clinical trial of Ampion. The plaintiff asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Securities and Exchange Commission Rule 10b-5, on behalf of a putative class of purchasers of the Company’s common stock from December 14, 2017 through August 7, 2018. Plaintiff in the Securities Class Action seeks unspecified damages, pre-judgment and post-judgment interest, and attorneys’ fees and costs. On September 27, 2019, the Court presiding over the Securities Class Action issued an order appointing a Lead Plaintiff and Lead Counsel, pursuant to the Private Securities Litigation Reform Act. Lead Plaintiff filed an amended complaint in late 2019. The Company filed a motion to dismiss the amended complaint on February 10, 2020. On March 26, 2020, Lead Plaintiff filed a brief in opposition to the Company’s motion to dismiss. The Company filed a reply to the Plaintiff’s brief in opposition on April 27, 2020. On September 10, 2018, a purported stockholder of the Company brought a derivative action in the United States District Court for the Central District of California, captioned Cetrone v. Macaluso, et al., Case No. 18-cv-07855 (the “Cetrone Action”), alleging primarily that the directors and officers of Ampio breached their fiduciary duties in connection with alleged misstatements and omissions regarding the AP-003 Phase III clinical trial of Ampion. On October 5, 2018, a purported stockholder of the Company brought a derivative action in the United States District Court for the District of Colorado, Theise v. Macaluso, et al., Case No. 18-cv-02558 (the “Theise Action”), which closely parallels the allegations in the Cetrone Action. A second derivative action was filed in the United States District Court for the District of Colorado and was consolidated with the Theise Action under the caption In re: Ampio Pharmaceuticals Inc. Stockholder Derivative Actions, Case No. 18-cv-02558. This consolidated action, and the Certrone Action in California, are stayed pending further developments in the Securities Class Action. The Company believes that all claims asserted are without merit and intends to defend these lawsuits vigorously. However, it is possible that additional actions will be filed in the future. The Company currently believes the likelihood of a loss contingency related to these matters is remote and given the fact of where the claims exist in the litigation process, the Company is not in the position to provide an estimate and/or range of potential loss .

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2020
Subsequent Events
Subsequent Events	Note 13 – Subsequent Events In May 2020, pursuant to the Company’s IND application submitted and received by the FDA in April 2020, the Company received follow-up correspondence from the FDA requesting that additional information be provided prior to the Company’s expected receipt of authorization to conduct a clinical study of nebulized Ampion in patients suffering from the serious COVID-19 complication of moderate to severe Acute Respiratory Distress Syndrome (“ARDS”). The Company is working diligently to respond. In April 2020, the Company received additional gross proceeds from the sale of 5.2 million shares of common stock in connection with the Sales Agreement of $2.7 million, which was offset by offering related costs of $0.1 million. In April 2020, the Company received loan proceeds of $543,900 under the PPP Loan (the “PPP Loan”). The PPP was established under the recently enacted Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) and is administered by the U.S. Small Business Administration (“SBA”). The PPP Loan to the Company was made through KeyBank National Association (the “Lender”). The term of the PPP Loan is two years. The annual interest rate is 1.0%. Payments of principal and interest on the PPP Loan will be deferred for the first six months of the loan term. The Company may apply for and be granted forgiveness for all or a portion of the PPP Loan. Such forgiveness will be determined, subject to limitations, based on the use of the loan proceeds for qualifying expenses, which include payroll costs, rent, and utility costs over the eight-week measurement period following receipt of the loan proceeds. The Company cannot give any assurance that it will obtain forgiveness of the PPP Loan in whole or in part. In the event that no amount or less than all of the PPP Loan is forgiven, commencing in November 2020, the Company will be required to make principal and interest payments totaling $22,900 per month over the remaining term of the PPP Loan, with the remaining balance, if any, due and payable at the end of the term. The Company may prepay the PPP Loan without penalty. The loan agreement evidencing the PPP Loan contains customary events of default relating to, among other things, payment defaults, or breaches of representations and warranties, or other provisions of the loan agreement. The occurrence of an event of default may trigger the immediate repayment of all amounts outstanding, collection of all amounts owing from the Company, and/or the Lender filing suit and obtaining a judgment against the Company. The SBA and the United States Treasury (“Treasury”) continue to develop and issue new and updated guidance regarding the PPP loan application process, including guidance regarding required borrower certifications and requirements for loans made under the PPP. In particular, subsequent to the funding of the PPP Loan, Treasury published guidance that specifically addressed the certification required to be made by each PPP loan applicant, including the Company: “current economic uncertainty makes this loan request necessary to support the ongoing operations of the Applicant.” The guidance indicated that “borrowers must make this certification in good faith, taking into account their current business activity and their ability to access other sources of liquidity sufficient to support their ongoing operations in a manner that is not significantly detrimental to the business.” The Company has re-assessed its certification in good faith, taking into account its current business activity and its ability to access other sources of liquidity sufficient to support its ongoing operations in a manner that is not significantly detrimental to the business, and, based on this reassessment, the Company believes that the PPP Loan is necessary to support the Company’s ongoing operations. However, as of the date hereof, neither the SBA nor Treasury has released any further interpretive guidance regarding the required borrower certification or any final regulations relating to the forgiveness of loans made under the PPP. In the absence of such guidance or final regulations, the Company cannot give any assurance that its certification will be adequate or that the PPP Loan will be forgivable in whole or in part.

Basis of Presentation (Policies

Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2020
Summary of Significant Accounting Policies
Impact of Global Pandemic	Impact of Global Pandemic In March 2020, the World Health Organization declared the outbreak of the novel coronavirus, COVID-19, a global pandemic. The ultimate extent to which COVID-19, and measures taken in response to it, will impact the Company’s business is highly uncertain and subject to change. The full extent of potential impacts on the Company’s business and product development, including clinical trials, financing activities and the global economy are still unknown and cannot be predicted due to the uncertain nature of the COVID-19 pandemic and its effects. However, these effects could have a material adverse impact on the Company’s business, operations, financial condition and results of operations.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts or foreign currency hedging arrangements. The Company maintains cash and cash equivalent balances in the form of bank demand deposits, United States federal government backed treasury securities and fully liquid money market fund accounts with financial institutions that management believes are creditworthy. The Company periodically monitors its cash positions with, and the credit quality of, the financial institutions with which it invests. During the three months ended March 31, 2020, and as consistent with prior reporting periods, the Company maintained balances in excess of federally insured limits.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, and related disclosures in the financial statements and accompanying notes. The Company bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions primarily include the Company’s accrual for its current Phase III clinical trial (the “AP-013 study”) of Ampion for treatment of severe OAK, projected future liquidity and resulting going concern position, warrant derivative liability and related periodic gains and losses, stock-based compensation, the projected useful lives and potential impairment of fixed assets, and the valuation allowance related to deferred tax assets. The Company develops these estimates using its judgment based upon the facts and circumstances known at the time.
Adoption of Recent Accounting Pronouncements	Adoption of Recent Accounting Pronouncements In August 2018, the FASB issued ASU 2018‑13, “ Fair Value Measurement - Disclosure Framework (Topic 820) ”. The updated guidance modified the disclosure requirements on fair value measurements. The updated guidance is effective for fiscal years beginning after December 15, 2019, including interim reporting periods within those fiscal years. The Company adopted ASU 2018-13 during the first quarter of 2020 and the adoption of this guidance did not have a material impact on the Company’s financial statements. Recent Accounting Pronouncements The Company reviewed the recent accounting pronouncements and determined that none of the recent accounting pronouncements were applicable. This Quarterly Report on Form 10-Q does not discuss recent pronouncements that are not anticipated to have a current and/or future impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

Prepaid Expenses and Other (Tab

Prepaid Expenses and Other (Tables)	3 Months Ended
	Mar. 31, 2020
Prepaid Expenses and Other
Schedule Of Prepaid Expenses and other balances	March 31, 2020 December 31, 2019 Clinical trial deposit $ 348,000 $ 946,000 Insurance premiums 229,000 502,000 BLA consulting services deposit 182,000 182,000 Other 146,000 29,000 Annual service agreements 81,000 25,000 Lease deposit 34,000 34,000 Total prepaid expenses and other $ 1,020,000 $ 1,718,000

Fixed Assets (Tables)

Fixed Assets (Tables)	3 Months Ended
	Mar. 31, 2020
Fixed Assets
Schedule of Fixed Assets	Fixed assets are recorded at cost and, once placed in service, are depreciated on the straight-line method over their estimated useful lives. Leasehold improvements are accreted over the shorter of the estimated economic life or related lease term. Fixed assets consist of the following: Estimated As of December 31, As of March 31, Useful Lives in Years 2019 Additions Disposals 2020 Manufacturing facility/clean room 3 - 8 $ 3,081,000 $ — $ — $ 3,081,000 Leasehold improvements 10 6,075,000 — — 6,075,000 Office furniture and equipment 5 - 10 520,000 — — 520,000 Lab equipment 5 - 8 1,137,000 — — 1,137,000 Less accumulated depreciation and amortization (6,065,000) (295,000) — (6,360,000) Fixed assets, net $ 4,748,000 $ (295,000) $ — $ 4,453,000
Schedule Of Depreciation expense	Depreciation and amortization expense for the respective periods is as follows: Three Months Ended March 31, 2020 2019 Depreciation and amortization expense $ 295,000 $ 365,000

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2020
Accounts Payable and Accrued Expenses
Schedule of accounts payable and accrued expenses	March 31, 2020 December 31, 2019 Accounts payable $ 1,226,000 $ 151,000 Clinical trial 2,563,000 3,288,000 Professional fees 377,000 317,000 Property taxes 25,000 96,000 Other 18,000 30,000 BLA consulting services 5,000 28,000 Insurance premiums — 21,000 Accrued compensation — 72,000 Director fees — 22,000 Accounts payable and accrued expenses $ 4,214,000 $ 4,025,000

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Summary of Commitments and Contingencies	Commitments and contingencies are described below and summarized by the following table: Total 2020 2021 2022 2023 2024 Thereafter Key clinical research trial obligations $ 2,193,000 $ 2,193,000 $ — $ — $ — $ — $ — BLA consulting services 1,143,000 — 1,143,000 — — — — Statistical analysis and programming consulting services 350,000 350,000 — — — — — Employment agreements 1,911,000 649,000 783,000 466,000 13,000 — — $ 5,597,000 $ 3,192,000 $ 1,926,000 $ 466,000 $ 13,000 $ — $ —
Schedule of further detail of the CRO contract	March 31, 2020 Original contract $ 6,180,000 Amendment to contract 4,075,000 Total Contract $ 10,255,000 Initial deposit (included in original contract amount) $ 861,000 Amendment to deposit 699,000 Expenses incurred applied to deposit (1,212,000) Remaining Deposit $ 348,000 Expenses incurred/accrued (includes expenses applied to deposit) $ 8,314,000 Total future commitment $ 1,941,000
Summary of reconciliation of the Company’s undiscounted payments for its facility lease and the carrying amount of the lease liability	The following table provides a reconciliation of the Company’s remaining undiscounted payments for its facility lease and the carrying amount of the lease liability presented in the balance sheet as of March 31, 2020: Facility Lease Payments 2020 2021 2022 2023 2024 Thereafter Remaining Facility Lease Payments $ 1,597,000 $ 253,000 $ 345,000 $ 355,000 $ 364,000 $ 280,000 $ — Less: Discount Adjustment (190,000) Total lease liability $ 1,407,000 Lease liability-current portion $ 265,000 Long-term lease liability $ 1,142,000
Lease Expense	The following table provides a reconciliation of the Company’s remaining ROU asset for its facility lease presented in the balance sheet as of March 31, 2020: Right-of-Use Asset Balance as of December 31, 2019 $ 1,003,000 Amortization (44,000) Balance as of March 31, 2020 $ 959,000 The Company recorded lease expense in the respective periods is as follows: Three Months Ended March 31, 2020 2019 Lease expense $ 67,000 $ 66,000

Warrants (Tables)

Warrants (Tables)	3 Months Ended
	Mar. 31, 2020
Warrants
Summary of Company's warrant activity	The following table summarizes the Company’s warrant activity: Weighted Weighted Average Number of Average Remaining Warrants Exercise Price Contractual Life Outstanding at December 31, 2019 7,116,000 $ 0.57 Warrants issued — $ — Warrants exercised — $ — Warrants expired — $ — Outstanding at March 31, 2020 7,116,000 $ 0.57 3.16

Fair Value Considerations (Tabl

Fair Value Considerations (Tables)	3 Months Ended
	Mar. 31, 2020
Fair Value Considerations [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table presents the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2020 and December 31, 2019, by level within the fair value hierarchy: Fair Value Measurements Using Level 1 Level 2 Level 3 Total March 31, 2020 Liabilities: Warrant derivative liability $ — $ — $ 1,233,000 $ 1,233,000 December 31, 2019 Liabilities: Warrant derivative liability $ — $ — $ 2,064,000 $ 2,064,000
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as Level 3 in the fair value hierarchy: Derivative Instruments Balance as of December 31, 2019 $ 2,064,000 Warrant exercises — Change in fair value (831,000) Balance as of March 31, 2020 $ 1,233,000

Common Stock (Tables)

Common Stock (Tables)	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Schedule of remaining authorized Shares	March 31, 2020 Authorized shares 300,000,000 Common stock outstanding 160,022,000 Options Outstanding 6,240,000 Warrants Outstanding 7,116,000 Reserved for issuance under 2019 Stock and Incentive Plan 9,516,000 Available shares 117,106,000 Average Stock Price: 30 day $ 0.48 60 day $ 0.57 90 day $ 0.60
Schedule of sale of stock under equity distribution agreement	Sales Agreement Total shares of common stock sold 1,241,000 Average price per share $ 0.58 Gross Proceeds $ 682,000 Commissions earned by placement agents (27,000) Legal/Audit fees (219,000) Net Proceeds $ 436,000

Equity (Tables)

Equity (Tables)	3 Months Ended
	Mar. 31, 2020
Summary of Stock Options Outstanding and Exercisable	The following table summarizes the Company’s stock option activity under both the 2010 Plan and 2019 Plan: Weighted Weighted Average Number of Average Remaining Aggregate Options Exercise Price Contractual Life Intrinsic Value Outstanding at December 31, 2019 6,000,000 $ 1.33 5.40 $ — Granted 340,000 $ 0.69 Forfeited (100,000) $ 1.70 Outstanding at March 31, 2020 6,240,000 $ 1.29 5.45 $ 1,350 Exercisable at March 31, 2020 5,717,000 $ 1.36 5.08 $ 1,350 The 100,000 stock options that were forfeited as of March 31, 2020 were issued under the 2010 Plan, which was cancelled as noted above. Therefore, these forfeited stock options were not added back to the 2019 Plan. Stock options outstanding at March 31, 2020 are summarized in the table below: Number of Weighted Weighted Average Options Average Remaining Range of Exercise Prices Outstanding Exercise Price Contractual Lives $0.40 - $2.00 5,212,000 $ 0.73 6.13 $2.01 - $5.00 840,000 $ 3.28 1.68 $5.01 - $8.62 188,000 $ 7.97 3.60 6,240,000 $ 1.29 5.45
Assumptions Used in Computing Fair Value of All Options Granted	The Company computes the fair value for all options granted or modified using the Black-Scholes option pricing model. To calculate the fair value of the options, certain assumptions are made regarding components of the model, including the fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to the valuation. The Company calculates its volatility assumption using the actual changes in the market value of its stock. Forfeitures are recognized as they occur. The Company’s historical option exercises do not provide a reasonable basis to estimate an expected term due to the lack of sufficient data. Therefore, the Company estimates the expected term by using the simplified method. The simplified method calculates the expected term as the average of the vesting term plus the contractual life of the options. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity. The Company computed the fair value of options granted during the period ended March 31, 2020, using the following assumptions: Expected volatility 130.73% - 131.18 % Risk free interest rate 1.62% - 1.67 % Expected term (years) 5.00 - 5.51
Summary of Stock-Based Compensation Expense	The following table summarizes stock-based compensation expense for the three months ended March 31, 2020 and 2019: Three Months Ended March 31, 2020 2019 Research and development expenses Stock-based compensation $ 59,000 $ — General and administrative expenses Issuance of common stock for services 80,000 60,000 Stock-based compensation 154,000 28,000 Total stock-based compensation $ 293,000 $ 88,000 Unrecognized expense at March 31, 2020 119,000 Weighted average remaining years to vest 0.52
2019 Stock plan
Stock Option Activity	The following table summarizes the activity of the 2019 Plan and the available options to be granted as of March 31, 2020: 2019 Plan Total shares reserved for equity awards 10,000,000 Options granted (484,000) Remaining shares available for future equity awards 9,516,000

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2020
Earnings Per Share
Schedule for the calculations of basic and diluted earnings per share	Three Months Ended March 31, 2020 2019 Net loss $ (5,179,000) $ (5,812,000) Less: decrease in fair value of investor warrants (831,000) — Loss available to common stockholders $ (6,010,000) $ (5,812,000) Basic and diluted weighted-average common shares outstanding 159,054,000 111,104,000 Add: dilutive effect of equity instruments 1,504,000 — Diluted weighted-average shares outstanding 160,558,000 111,104,000 Earnings per share – basic $ (0.03) $ (0.05) Earnings per share – diluted $ (0.04) $ (0.05)
Potentially dilutive securities, excluded	Three Months Ended March 31, 2020 2019 Outstanding stock options 5,948,000 5,426,000 Warrants to purchase shares of common stock 5,904,000 22,233,000 Total potentially dilutive shares of common stock 11,852,000 27,659,000

Going Concern (Detail)

Going Concern (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018
Going Concern
Cash and Cash Equivalents, at Carrying Value	$ 2,415,000		$ 6,532,000
Net Income (Loss) Attributable to Parent	(5,179,000)	$ (5,812,000)
Operating Expenses	6,021,000	2,676,000
Gain (Loss) on Derivative Instruments, Net, Pretax	831,000	(3,160,000)
Interest Income (Expense), Nonoperating, Net	11,000	24,000
Net Cash Provided by (Used in) Operating Activities	(4,553,000)	(2,440,000)
Retained Earnings (Accumulated Deficit)	(189,812,000)		(184,633,000)
Stockholders' deficit	1,993,000	$ (468,000)	$ 6,443,000	$ 5,236,000
Gross proceeds	700,000
Cash requirements for fixed, on-going expenses such as payroll, legal and accounting, patents and overhead at an average cash burn rate	$ 800,000

Prepaid Expenses and Other (Det

Prepaid Expenses and Other (Detail) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Prepaid Expenses and Other
Clinical trial deposit	$ 348,000	$ 946,000
Insurance premiums	229,000	502,000
Biologics License Application ("BLA") consulting services deposit	182,000	182,000
Other	146,000	29,000
Annual service agreements	81,000	25,000
Lease deposit	34,000	34,000
Total prepaid expenses and other	$ 1,020,000	$ 1,718,000

Fixed Assets (Detail)

Fixed Assets (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Less accumulated depreciation and amortization	$ (6,360,000)	$ (6,065,000)
Less accumulated depreciation and amortization Fixed assets net	295,000
Fixed assets, net	4,453,000	4,748,000
Manufacturing facility/ clean room
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 3,081,000	3,081,000
Manufacturing facility/ clean room | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Manufacturing facility/ clean room | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	8 years
Leasehold improvements
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 6,075,000	6,075,000
Estimated useful lives	10 years
Office furniture and equipment
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 520,000	520,000
Office furniture and equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Office furniture and equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	10 years
Lab equipment
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 1,137,000	$ 1,137,000
Lab equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Lab equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	8 years

Fixed Assets - Depreciation and

Fixed Assets - Depreciation and Amortization Expense (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Fixed Assets
Depreciation and Amortization Expense	$ 295,000	$ 365,000

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses (Detail) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Accounts Payable and Accrued Expenses
Accounts payable	$ 1,226,000	$ 151,000
Clinical trial	2,563,000	3,288,000
Professional fees	377,000	317,000
Property taxes	25,000	96,000
Other	18,000	30,000
BLA consulting services	5,000	28,000
Insurance premiums		21,000
Accrued compensation		72,000
Directors Fees		22,000
Accounts payable and accrued expenses	$ 4,214,000	$ 4,025,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	1 Months Ended
	Jan. 31, 2020USD ($)item	Sep. 30, 2019USD ($)item	Jun. 30, 2019USD ($)item	Mar. 31, 2019USD ($)item	Dec. 31, 2013USD ($)	Mar. 31, 2020USD ($)	Feb. 29, 2020USD ($)	Dec. 31, 2019USD ($)	May 31, 2019USD ($)	Mar. 31, 2018USD ($)
Commitments and Contingencies [Line Items]
Contractual obligation						$ 5,597,000
Facility Lease Incremental Borrowing Rate						5.75%
Prepaid Clinical Trial Deposits						$ 348,000		$ 946,000
Prepaid consulting services deposits						182,000		$ 182,000
Newly Leased Office Space and Manufacturing Facility [Member]
Commitments and Contingencies [Line Items]
Non-cancellable operating lease period					125 months
Lease initial base rent per month					$ 23,000
Total base rent over the term of the lease					$ 3,300,000
Key Clinical Research Trial Obligations
Commitments and Contingencies [Line Items]
Contractual obligation						2,193,000
CRO
Commitments and Contingencies [Line Items]
Contract amount	$ 10,300,000			$ 6,200,000		10,255,000
Amount Incurred Against Contract Obligation						8,314,000
Contractual obligation						1,941,000
Number Of Patients | item	1,034			724
Increase in existing contract	$ 4,100,000
Patient recruitment services company
Commitments and Contingencies [Line Items]
Contract amount		$ 377,000	$ 264,000			718,000	$ 698,000
Amount Incurred Against Contract Obligation						20,000
Contractual obligation						0
Cumulative costs						718,000
Number Of Patients | item		1,034	724
Clinical staff outsourcing firm
Commitments and Contingencies [Line Items]
Contract amount						463,000
Amount Incurred Against Contract Obligation						211,000
Contractual obligation						252,000
BLA consulting services
Commitments and Contingencies [Line Items]
Contract amount						1,100,000				$ 1,200,000
Amount Incurred Against Contract Obligation						69,000
Contractual deposit Commitment										364,000
Prepaid consulting services deposits										$ 182,000
Statistical analysis and programming consulting services
Commitments and Contingencies [Line Items]
Contract amount									$ 578,000
Amount Incurred Against Contract Obligation						228,000
Contractual obligation						$ 350,000

Commitments and Contingencies_2

Commitments and Contingencies - Summary of Commitments and Contingencies (Detail)	Mar. 31, 2020USD ($)
Commitment And Contingencies [Line Items]
2020	$ 3,192,000
2021	1,926,000
2022	466,000
2023	13,000
2024	0
Thereafter	0
Total	5,597,000
Key Clinical Research Trial Obligations
Commitment And Contingencies [Line Items]
2020	2,193,000
2022	0
2023	0
2024	0
Thereafter	0
Total	2,193,000
BLA consulting services
Commitment And Contingencies [Line Items]
2021	1,143,000
2022	0
2023	0
2024	0
Thereafter	0
Total	1,143,000
Statistical analysis and programming consulting services
Commitment And Contingencies [Line Items]
2020	350,000
2022	0
2023	0
2024	0
Thereafter	0
Total	350,000
Employment Agreements
Commitment And Contingencies [Line Items]
2020	649,000
2021	783,000
2022	466,000
2023	13,000
2024	0
Thereafter	0
Total	$ 1,911,000

Commitments and Contingencies_3

Commitments and Contingencies - CRO contract (Detail) - USD ($)	Mar. 31, 2020	Jan. 31, 2020	Mar. 31, 2019
Commitments and Contingencies [Line Items]
Total	$ 5,597,000
CRO
Commitments and Contingencies [Line Items]
Original contract	6,180,000
Amendment to contract	4,075,000
Total Contract	10,255,000	$ 10,300,000	$ 6,200,000
Initial deposit (included in original contract amount)	861,000
Amendment to deposit	699,000
Expenses incurred applied to deposit	(1,212,000)
Remaining Deposit	348,000
Expenses incurred/accrued (includes expenses applied to deposit)	8,314,000
Total	$ 1,941,000

Commitments and Contingencies_4

Commitments and Contingencies - Employment Agreements (Detail) - USD ($)	Dec. 14, 2019	Sep. 16, 2019	Jul. 09, 2019
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Term of employment agreement (in years)	3 years
Annual Salary	$ 300,000
Chief Operating Officer [Member]
Related Party Transaction [Line Items]
Term of employment agreement (in years)		2 years
Annual Salary		$ 280,000
Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Term of employment agreement (in years)			3 years
Annual Salary			$ 285,000

Commitments and Contingencies_5

Commitments and Contingencies - Summary of Reconciliation of Company's Undiscounted Payments for Facility Lease and Carrying Amount of Lease Liability (Detail) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2020	$ 253,000
2021	345,000
2022	355,000
2023	364,000
2024	280,000
Remaining Facility Lease Payments	1,597,000
Less: Discount Adjustment	(190,000)
Total lease liability	1,407,000
Lease liability - current portion	265,000	$ 259,000
Long-term lease liability	$ 1,142,000	$ 1,210,000

Commitments and Contingencies_6

Commitments and Contingencies - Lease Expense (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Balance as of December 31, 2019	$ 1,003,000
Amortization	(44,000)
Balance as of March 31, 2020	959,000
Lease expense	$ 67,000	$ 66,000

Warrants - (Detail)

Warrants - (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Class of Warrant or Right [Line Items]
Warrant derivative liability	$ 1,233,000		$ 2,064,000
Proceeds from warrant exercises	$ 0	$ 20,000
Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants, Exercise price	$ 0.57		$ 0.57

Warrants - Warrants Activity (D

Warrants - Warrants Activity (Detail) - $ / shares shares in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Number of Warrants Outstanding
Number of Warrants Outstanding, Ending Balance	7,116
Warrants [Member]
Number of Warrants Outstanding
Number of Warrants Outstanding, Beginning Balance	7,116
Number of Warrants Outstanding, Ending Balance	7,116	7,116
Warrants, Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 0.57
Weighted Average Exercise Price, Outstanding Ending Balance	$ 0.57	$ 0.57
Weighted Average Remaining Contractual Life
Weighted Average Remaining Contractual Life, Warrants Outstanding	3 years 1 month 28 days	3 years 4 months 28 days
Equity based-warrants
Number of Warrants Outstanding
Number of Warrants Outstanding, Ending Balance	2,700
Liability warrants
Number of Warrants Outstanding
Number of Warrants Outstanding, Ending Balance	4,400

Warrants - Assumptions for Warr

Warrants - Assumptions for Warrants Issued (Detail) - shares shares in Thousands	Mar. 31, 2020	Dec. 31, 2019
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Number of shares	7,116
Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Number of shares	7,116	7,116

Fair Value Considerations - Fin

Fair Value Considerations - Financial Assets and Liabilities (Detail) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
LIABILITIES
Warrant derivative liability	$ 1,233,000	$ 2,064,000
Fair Value, Inputs, Level 1 [Member]
LIABILITIES
Warrant derivative liability	0	0
Fair Value, Inputs, Level 2 [Member]
LIABILITIES
Warrant derivative liability	0	0
Fair Value, Inputs, Level 3 [Member]
LIABILITIES
Warrant derivative liability	$ 1,233,000	$ 2,064,000

Fair Value Considerations - Set

Fair Value Considerations - Sets Forth a Reconciliation of Changes (Detail)	3 Months Ended
	Mar. 31, 2020USD ($)
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]
Balance as of December 31, 2019	$ 2,064,000
Change in fair value	(831,000)
Balance as of March 31, 2020	$ 1,233,000

Common Stock (Summarizes the Co

Common Stock (Summarizes the Company's remaining authorized shares available - (Detail) - $ / shares	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Components Of Common Stock [Line Items]
Authorized shares	300,000,000	300,000,000
Common stock outstanding	160,022,000	158,645,000
Options Outstanding	6,240,000	6,000,000
Warrants Outstanding	7,116,000
Reserved for issuance under 2019 Plan	9,516,000
Available Shares	117,106,000
30 day
Components Of Common Stock [Line Items]
Average stock price	$ 0.48
60 day
Components Of Common Stock [Line Items]
Average stock price	0.57
90 day
Components Of Common Stock [Line Items]
Average stock price	$ 0.60

Common Stock (Shelf Registratio

Common Stock (Shelf Registration Narrative) (Detail) - Shelf Registration shares in Millions, $ in Millions	1 Months Ended
	Mar. 31, 2017USD ($)shares
Components of common Stock [Line Items]
Common stock and warrants | $	$ 100
Common stock to be sold by directors and management in future public offerings | shares	5

Common Stock (Sales Agreement N

Common Stock (Sales Agreement Narrative) (Detail) - Sale Agreement (ATM) $ in Millions	Feb. 29, 2020USD ($)
Class of Stock [Line Items]
Maximum aggregate offering price of equity securities	$ 50
Percentage of commission	4.00%
Sales Agreement Agent [Member]
Class of Stock [Line Items]
Percentage of commission	2.00%

Common Stock (Summary of Compan

Common Stock (Summary of Company’s sales under the Equity Distribution Agreement) (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Class of Stock [Line Items]
Gross Proceeds	$ 682,000	$ 0
Net Proceeds	$ 436,000
Equity Distribution Agreement
Class of Stock [Line Items]
Total shares of common stock sold	1,241,000
Average price per share	$ 0.58
Gross Proceeds	$ 682,000
Commissions earned by placement agent	(27,000)
Legal/Audit fees	$ (219,000)

Common Stock (Common Stock Issu

Common Stock (Common Stock Issued for Services) (Detail) - USD ($) shares in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Components of common Stock [Line Items]
Stock Issued During Period, Value, Issued for Services	$ 80,000	$ 60,000
Common Stock Issued for Services [Member] | Non Employee Directors
Components of common Stock [Line Items]
Stock Issued During Period, Shares, Issued for Services	136	136
Stock Issued During Period, Value, Issued for Services	$ 80,000	$ 60,000

Equity - Activity of Plan (Deta

Equity - Activity of Plan (Detail) - shares	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted	(340,000)
2019 Stock plan | Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares reserved for equity awards	10,000,000	10,000,000
Options granted	(484,000)
Remaining shares available for future equity awards	9,516,000

Equity - Stock Option Activity

Equity - Stock Option Activity (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Number of Options
Number of Options, Beginning Balance	6,000,000
Number of Options, Granted	340,000
Number of Options, Forfeited	(100,000)
Number of Options, Ending Balance	6,240,000	6,000,000
Number of Options, Exercisable	5,717,000
Weighted Average Exercise Price
Weighted Average Exercise Price, Beginning Balance	$ 1.33
Weighted Average Exercise Price, Granted	0.69
Weighted Average Exercise Price, Forfeited	1.70
Weighted Average Exercise Price, Ending Balance	1.29	$ 1.33
Weighted Average Exercise Price, Exercisable	$ 1.36
Weighted Average Remaining Contractual Life, Outstanding	5 years 5 months 12 days	5 years 4 months 24 days
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.69
Weighted Average Remaining Contractual Life, Exercisable	5 years 29 days
Aggregate Intrinsic Value, Outstanding	$ 1,350
Aggregate Intrinsic Value, Exercisable	$ 1,350

Equity - Summary of Stock Optio

Equity - Summary of Stock Options Outstanding and Exercisable (Detail) - Employee Stock Option	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options Outstanding | shares	6,240,000
Weighted Average Exercise Price	$ 1.29
Weighted Average Remaining Contractual Lives	5 years 5 months 12 days
$0.40 - $2.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options Outstanding | shares	5,212,000
Weighted Average Exercise Price	$ 0.73
Weighted Average Remaining Contractual Lives	6 years 1 month 17 days
Range of Exercise Prices Lower	$ 0.40
Range of Exercise Prices Upper	$ 2
$2.01 - $5.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options Outstanding | shares	840,000
Weighted Average Exercise Price	$ 3.28
Weighted Average Remaining Contractual Lives	1 year 8 months 5 days
Range of Exercise Prices Lower	$ 2.01
Range of Exercise Prices Upper	$ 5
$5.01 - $8.93 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options Outstanding | shares	188,000
Weighted Average Exercise Price	$ 7.97
Weighted Average Remaining Contractual Lives	3 years 7 months 6 days
Range of Exercise Prices Lower	$ 5.01
Range of Exercise Prices Upper	$ 8.62

Equity - Assumptions Used in Co

Equity - Assumptions Used in Computing Fair Value of All Options Granted (Detail)	3 Months Ended
	Mar. 31, 2020
Expected volatility, Minimum	130.73%
Expected volatility, Maximum	131.18%
Risk free interest rate, Minimum	1.62%
Risk free interest rate, Maximum	1.67%
Minimum
Expected term (years)	5 years
Maximum
Expected term (years)	5 years 6 months 4 days

Equity - Summary of Stock-Based

Equity - Summary of Stock-Based Compensation Expense (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized expense at December 31, 2019	$ 119,000
Weighted average remaining years to vest	6 months 7 days
Research and Development Expenses [Member] | Stock Based Compensation [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 59,000
General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	293,000	$ 88,000
General and Administrative Expenses [Member] | Common Stock Issued for Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	80,000	60,000
General and Administrative Expenses [Member] | Stock Based Compensation [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 154,000	$ 28,000

Earnings Per Share - Narrative

Earnings Per Share - Narrative (Detail) - shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	11,852,000	27,659,000
Employee Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	5,948,000	5,426,000
Warrant to purchase shares of common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	5,904,000	22,233,000

Earnings Per Share (Detail)

Earnings Per Share (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Earnings Per Share
Net Income (loss)	$ (5,179,000)	$ (5,812,000)
Less: decrease in fair value of investor warrants	(831,000)
Income (loss) available to common stockholders	$ (6,010,000)	$ (5,812,000)
Basic weighted-average common share outstanding	159,054,000	111,104,000
Add: dilutive effect of equity instruments	1,504,000
Diluted weighted-average shares outstanding	160,558,000	111,104,000
Earnings per share - basic	$ (0.03)	$ (0.05)
Earnings per share - diluted	$ (0.04)	$ (0.05)

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - Subsequent Event shares in Millions	1 Months Ended
	Apr. 30, 2020USD ($)shares
Paycheck Protection Program [Member]
Subsequent Event [Line Items]
Proceeds from Issuance of Long-term Debt	$ 543,900
Debt Instrument, Term	2 years
Debt Instrument, Interest Rate, Stated Percentage	1.00%
Debt Instrument, Periodic Payment	$ 22,900
Sale Agreement (ATM)
Subsequent Event [Line Items]
Issuance of common stock (Shares) | shares	5.2
Issuance of common stock	$ 2,700,000
Offering related costs	$ 100,000